22:12 , Jul 11, 2019 |  BC Innovations  |  Translation in Brief

PARP inhibitors plus senolytics: a double hit on cancer

A new approach to synthetic lethality aims to overcome resistance to PARP inhibitors by pairing them with senolytic agents, marking one of the first moves beyond DNA damage repair combinations. PARP inhibitors hinder DNA damage...
22:14 , Jun 14, 2019 |  BioCentury  |  Emerging Company Profile

Sherlock: Leveraging CRISPR, synthetic biology for diagnostics

By taking advantage of two hot technologies, Sherlock is developing a pair of molecular diagnostics that can be used alone or together to rapidly and accurately detect disease in a wide variety of applications. Sherlock...
03:07 , Jun 7, 2019 |  BC Innovations  |  Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
00:51 , May 31, 2019 |  BC Innovations  |  Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
22:52 , Apr 26, 2019 |  BC Extra  |  Company News

European regulatory roundup: CHMP opinions and a Portola approval

EMA's CHMP recommended a basket of approvals, including Dovato dolutegravir/lamivudine, Libtayo cemiplimab and two orphan therapies. Also Friday, the European Commission granted conditional approval to Ondexxya andexanet alfa from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) to reverse...
17:29 , Apr 22, 2019 |  BC Innovations  |  Distillery Therapeutics

STAG2 identified as target in glioblastoma and Ewing sarcoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; sarcoma Cell culture studies suggest inhibiting STAG2 could sensitize glioblastoma and Ewing sarcoma to agents that disrupt repair of DNA double-strand (dsDNA) breaks. In two human glioblastoma and one...
00:27 , Apr 13, 2019 |  BioCentury  |  Tools & Techniques

ctDNA inches toward new applications

After establishing itself as a key tool for tumor profiling and patient stratification, circulating tumor DNA is now beginning to make the move into monitoring response to therapy, where it promises an early read of...
22:21 , Apr 10, 2019 |  BC Extra  |  Preclinical News

WRN identified as new synthetically lethal target

As part of an effort to exploit synthetically lethal interactions for therapeutic use, three groups independently identified a new target, a DNA helicase called WRN, in cancers with DNA microsatellite instability. Two teams -- one...
20:25 , Apr 5, 2019 |  BC Week In Review  |  Clinical News

Clovis' PARP inhibitor leads to PFS of 9.1 months in pancreatic cancer

Clovis reported at AACR that first-line maintenance treatment with Rubraca rucaparib led to a median progression-free survival of 9.1 months from the start of Rubraca therapy among 19 evaluable pancreatic cancer patients in an interim...
22:01 , Mar 15, 2019 |  BioCentury  |  Product Development

Broadening the PARP playing field

With its latest clinical win for Lynparza, AstraZeneca is leading the field in stretching the use of PARP inhibitors beyond tumors that carry BRCA mutations. The results highlight one piece of a broader strategy companies...